New Users          



Menopause in the New Millennium

Resources & References

Table Of Contents



Top of Page


Online Papers

Top of Page



  • ACOG Practice Bulletin.(2001). Clinical Management Guidelines for Obstetrician-Gynecologists. Use of botanicals for management of menopausal symptoms. Obstet Gynecol 97:suppl 1-11.
  • Adams MR, Register TC, Golden DL, Wagner JD, Williams JK. (1997). Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated estrogens on coronary artery atherosclerosis. Arteriosler Thomb Vasc Biol, 17:217-221.
  • American College of Obstetricians and Gynecologists. (2002). Statement on the estrogen plus progestin trial of the Women's Health Initiative. ACOG News Release. July 9.
  • Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women's Health Initiative Steering Committee. (2004). Effects of conjugated equine estrogen in post menopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA, 291:1701-1712.
  • Asbury EA, Chandrruangphen P, Collins P. (2006).in quality of life and psychological well-being in previously inactive postmenopausal women: a pilot study. Menopause. Jul-Aug;13(4):561-7.
  • Avis NE, Brambilla D, McKinlay SM, et al. (1994). A longitudinal analysis of the association between menopause and depression: results from the Massachusetts Women's Health Study. Ann Epidemiol, 41:214-220.
  • Backstrom, T. (1995). Symptoms related to the menopause and sex steroid treatments. Ciba Found Symp, 191:171-180.
  • Barrett-Connor, E. (1997). Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. Circulation, 95:252-264.
  • Barrett-Connor, E. and Bush, TL. (1991). Estrogen and coronary heart disease in women. JAMA, 265:1861-1867.
  • Barrett-Connor, E. and Grady, D. (1998). Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health, 19:55-72.
  • Barrett-Connor, E. and Stuenkel, C. (1999). Hormones and heart disease in Women: Heart and Estrogen/progestin Replacement Study in perspective. J Clin Endocrinol Metab, 84:1848-1853.
  • Barrett-Connor E, Stuenkel CA. (2001). Hormone replacement therapy (HRT): risks and benefits. Int JEpidemiol, 30:423-426.
  • Blumenthal, SJ. (1994). Women and depression. J Womens Health Gend Based Med, 3:467-479.
  • Booth-LaForce C, Thurston RC, Taylor MR.(2007). A pilot study of a Hatha yoga treatment for menopausal symptoms. Maturitas. Jul 20;57(3):286-95.
  • Burt VK, Altschuler LL, Rasgon N. (1998). Depressive symptoms in the perimenopause: prevalence, assessment, and guideline for treatment. Harvard Rev Psychiatry, 6(3):121-132.
  • Bush, T. (1990). The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci, 592:263-271.
  • Castellsague J, Perez Gutthann S, Garcia Rodriguez LA. (1998). Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. Drug Safety, 18:117-123.
  • Cauley JA, Gutai JP, Kuller LH, Powell JG. (1990). The relation of endogenous sex steroid hormone concentrations to serum lipid and lipoprotein levels in postmenopausal women. Am J Epidemiol, 132:884-894.
  • Charney, DA and Dara, A. (1996). The psychoendocrinology of menopause in cross-cultural perspective. Transcultural Psychiatric Research Review, 33(4):413-434.
  • Cheng G, Wilczek B, Warner M, Gustafsson JA, Landgren BM. (2007).Isoflavone treatment for acute menopausal symptoms. Menopause May-Jun;14(3 Pt 1):468-73.
  • Clarke KW, Gray D, Keating NA, Hampton JR (1994). Do women with acute myocardial infarction receive the same treatment as men? Br Med J, 309:563-566.
  • Classen, V. (1983). Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol, 15(Suppl 3):49s-55s.
  • Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. (1987). Menopause and the risk of coronary heart disease in women. N Engl J Med, 316:1105-1110.
  • Contestabile E, Derzko C. (2001). Canadian consensus on menopause and perimenopause. J Obstet Gynaecol Can 23(9):836-841.
  • Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ. (1993). Population-based study of survival after osteoporotic fractures. Am J Epidemiol, 137:1001-1005.
  • CQIN Investigators. (1995). Low incidence of assessment and modification of risk factors in acute care patients at high risk for cardiovascular events, particularly among females and the elderly. Am J Cardiol, 76:570-573.
  • Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP. (1999). Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation, 100:717-722.
  • DeFeudis, F. (1991). Ginkgo biloba Extract. Pharmacological Activities and Clinical Applications. Elsevier: Paris.
  • Dennerstein L, Dudley EC, Hopper JL, Guthrie JR, Burger HG. (2000). A prospective population-based study of menopausal symptoms. Obstet Gynecol, 96:351-358.
  • Dennerstein L, Smith AMA, Morse C. (1994). Psychological well-being, mid-life and the menopause. Maturitas, 20:1-11.
  • Ditkoff EC, Crary WG, Cristo M, et al.. (1991). Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol, 78:991-995.
  • Freedman, RR and Woodward, S. (1991). Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am J Obstet Gynecol, 167:436-439.
  • Fuyuki T, Ohta H, Makita K, Takamatsu K, Horiguchi F, Nozawa S. (1998). Hormone replacement therapy on climacteric symptoms. Obstet Gynecol Ther, 76(suppl):158-165.
  • Geller, SE and Studee, L.(2005). Botanical and dietary supplements for menopausal symptoms: what works, what does not. J Womens Health (Larchmt). Sep;14(7):634-49.
  • Gerhard M, Walsh BW, Tawakol A, Haley EA, Creager SJ, Seely EW, Ganz P, Creager MA (1998).Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation, 98:1158-1163.
  • Giugliano D, Ceriello A, Esposito K.(2006). The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll. Cardiol. Aug 15;48(4):677-85. Epub 2006 Jul 24.
  • Gonzales, GF and Carillo, C. (1993). Blood serotonin levels in postmenopausal women ; effect of age and serum oestradiol therapy levels. Maturitas, 17:23-29.
  • Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA. (1989). High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 79:8-15.
  • Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. (1995). Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol, 85:304-313.
  • Greendale GA, Lee NP, Arriola ER. (1999). The menopause. Lancet, 353:571-580.
  • Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. (1986). Post-menopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med, 335:453-461.
  • Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. (1997). Postmenopausal hormone therapy and mortality. N Engl J Med, 223:1769-1775.
  • Grodstein F, Manson JE, Stampfer MJ. (1999). Postmenopausal hormones and recurrence of coronary events in the Nurses' Health Study. Circulation, 100(suppl):1-871.
  • Haimov-Kochman, R and Hochner-Celnikier, D. (2005). Hot flashes revisited: pharmacological and herbal options for hot flashes management. What does the evidence tell us? Acta Obstet Gynecol Scand. Oct;84(10):972-9.
  • Harlow BL, Cohen LE, Otto MW, et al.. (1999). Prevalence and predictors of depressive symptoms in older premenopausal women. Arch Gen Psychiatry, 56:418-424.
  • Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, Aragaki AK, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG, Women's Health Initiative Investigators. (2003). Effects of estrogen plus progestin on health-related quality of life. N Engl J Med, 348(19):1839-1854.
  • Heart and Stroke Foundation of Canada. (1997). Heart disease and stroke in Canada. Statistics Canada, Health Canada, Heart and Stroke Foundation of Canada. Ottawa.
  • Heart and Stroke Foundation of Canada. (1999). The changing face of heart disease and stroke in Canada. Ottawa.
  • Herrington DM, Reboussin DM, Brosnihan BK, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. (2000). Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med, 343:552-559.
  • Hochman JS, Tamis JE, Thompson TD, et al. (2000). Sex, clinical presentation and outcome in patients with acute coronary syndromes. N Engl J Med, 341:226-232.
  • Holinka, CF and Pickar, JH. (2002). Clinical studies in hormone replacement therapy: Treatment of the postmenopausal woman. 2nd edition. Edited by: Lobo RA. Philadelphia: Lippincott Williams & Wilkins: 629-637.
  • Holroyd-Leduc JM, Kapral MK, Austin P, Tu JV. (2000). Sex differences and similarities in the management and outcomes of stroke patients. Stroke, 31:1833-1837.
  • Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, Ransohoff DF, Sindelar J. (1990). Treatment adherence and risk of death after a myocardial infarction. Lancet, 336:452-455.
  • Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, 280:605-613.
  • Hunter, M. (1992). The south-east longitudinal study of the climacteric and postmenopause. Maturitas, 14:143-155.
  • Kapral, MK and Redelmeier, DA. (2000). Carotid endarterectomy for women and men. J Women's Health Gender-Based Med, 9:1-8.
  • Kaufert, P, Gilbert P, Tate, R. (1992). The Manitoba project: a reexamination of the link between menopause and depression in mid-aged women. Maturitas, 14:143-155.
  • Khalsa, SB (2004). Treatment of chronic insomnia with yoga: a preliminary study with sleep-wake diaries. Appl Psychophysiol Biofeedback. Dec;29(4):269-78.
  • Klaiber EL, Broverman DM, Vogel W, et al.. (1996). Individual differences in changes in mood and platelet monoamine oxidase (MAO) activity during hormonal replacement therapy in menopausal women. Psychoneuroendocrinology, 21:575-592.
  • Kligler, B.(2003). Black cohosh. Am Fam Physician. Jul 1;68(1):114-6.
  • Kronenberg, F. (1994). Hot flashes: phenomenology, quality of life, and search for treatment options. Exp Gerontol, 29:319-336.
  • Kroon UB, Silfverstolpe G, Tengborn L. (1994). The effects of transdermal estradiol and oral conjugated estrogens on hemostasis variables. Thromb Haemost, 71:420-423.
  • Leonetti HB, Longo S, Anasti JN. (1999). Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol, 94:225-228.
  • Lerner, DJ and Kannel, WB (1986). Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J, 111:383-390.
  • Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KPL, Booth N, Constantinou AI, Pezzuto JM, Fong HHS, et al.. (2001). Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem, 49:2472-2479.
  • Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ. (2000). Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. Lancet, 356:2059-2063.
  • Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novothy PJ, Rummans TA. (2002). Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol, 20:1578-1583.
  • Low Dog, T.(2005). Menopause: a review of botanical dietary supplements. Am J Med. Dec 19;118 Suppl 12B:98-108.
  • MacLennan, A and Lester S, Moore V. (2002). Oral oestrogen replacement therapy versus placebo for hot flushes (Cochrane Review). In The Cochrane Library Issue 2 Oxford: Update Software.
  • Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. (1996). Prior to use of estrogen replacement therapy, are users healthier than non-users? Am J Epidemiol, 143:971-978.
  • McKee, J and Warber, SL (2005). Integrative therapies for menopause. South Med J. Mar;98(3):319-26.
  • McKinlay SM, Brambilla DJ, Posner JG. (1992). The normal menopausal transition. Maturitas, 14:103-115.
  • McKinlay, SM and Jefferys, M. (1974). The menopausal syndrome. Br J Prev Soc Med 1974, 28:108-115.
  • Melton LJ, Chrischilles EA, Cooper C, Lane AW, Riggs BL: Perspective. (1992). How many women have osteoporosis? J Bone Miner Res, 7:1005-1010.
  • Mendelsohn, ME and Karas, RH. (1999). The protective effects of estrogen on the cardiovascular system. N Engl J Med, 340:1801-1811.
  • Meschia M, Bruschi F, Soma M, Amicarelli F, Paoletti R, Crosignani P. (1998). Effects of oral and transdermal hormone replacement therapy on lipoprotein (a) and lipids: a randomized controlled trial. Menopause, 5:157-162.
  • Messina, M and Hughes, C.(2003). Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. J Med Food. Spring;6(1):1-11.
  • Mosca, L. (2000). The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Intern Med, 160: 2263-2272.
  • Mosca L, Grundy SM, Judelson D, et al. (1999). Guide to preventive cardiology for women. Circulation, 99:2480-2484.
  • Mosca L, Manson JE, Sutherland SE, et al.. (1997). Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Circulation, 96:2468-2482.
  • Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. (2002). Postmenopausal hormone replacement therapy: scientific review. JAMA, 288:872-881.
  • Neugarten BL, Kraines RJ. (1965). Menopausal symptoms in women of various ages. Psychosom Med, 7:266-273.
  • Newton KM, Reed SD, LaCroix AZ, et al (2006).. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo. Annals of Internal Medicine, 145(12):869-879.
  • North American Menopause Society. (2000). Clinical challenges of perimenopause: consensus opinion of the North American Menopause Society. Menopause, 7:5-13.
  • North American Menopause Society. (2002). Amended Report from the NAMS Advisory Panel on Postmenopausal Hormone Therapy. North American Menopause Society Advisory Panel October 6, 2002
  • Novaes C, Almeida OP, de Melo NR. (1998). Mental health among perimenopausal women attending a menopause clinic: possible association with premenstrual syndrome? Climacteric, 1:264-270.
  • Novaes C, Almeida OP. (1999). Premenstrual syndrome and psychiatric morbidity at the menopause. JPsychosom Obstet Gynecol, 20:56-57.
  • Obermeyer, CM. (2000). Menopause across cultures: a review of the evidence. Menopause, 7:184-192.
  • Oken BS, Zajdel D, Kishiyama S, Flegal K, Dehen C, Haas M, Kraemer DF, Lawrence J, Leyva J.(2006). Randomized, controlled, six-month trial of yoga in healthy seniors: effects on cognition and quality of life. Altern Ther Health Med. Jan-Feb;12(1):40-7.
  • Pan B, Kato Y, Sengoku K, Takuma N, Niizeki N, Ishikawa M. (2004). Treatment of climacteric symptoms with herbal formulas of traditional Chinese medicine. Gynecol Obstet Invest, 57:144-148.
  • Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass ML, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D, WHIMS Investigators. (2003). Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA, 289(20):2663-2672.
  • Robinson, GE. (1996). Cross-cultural aspects of menopause. J Nerv Ment Dis, 184:453-458.
  • Robinson, GE and Stirtzinger, R. (1997). Psychoeducational program and support groups at transition to menopause:. In: A clinician's guide to menopause Edited by: Stewart DE, Robinson GE. Washington DC: American Psychiatric Press Inc: 165-179.
  • Rockliff, BW. (1969). A brief self-rating questionnaire for depression (SRQ-D). Psychosomatics, 10:236-243.
  • Rossouw, JE. (1999). What we still need to learn about hormone replacement therapy. Infertility Reprod Med Clin North Am, 10:189-209.
  • Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 88:321-333.
  • Sarrel, P. & Whitehead, M.I. (1985). Sex and menopause: Defining the issues. Maturitas, 7 (3), 217-224.
  • Scarabin P-Y, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M (1997). Effects of oral and transdermal estrogen/progesterone concentrations on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol, 17:3071-3078.
  • Schmidt PJ, Nieman L, Danaceau MA, Tobin MB, Roca CA, Murphy JH, Rubinow DR. (2000). Estrogen replacement in perimenopause related depression: a preliminary report. Am J Obstet Gynecol, 183:414-420.
  • Schmidt PJ, Roca CA, Bloch M, et al..(1997). The perimenopause and affective disorders. Sem Reprod Endocrinol, 15:91-100.
  • Schmidt PJ, Rubinow DR. (1991). Menopause-related affective disorder: a justification for further study. AmJ Psychiatry, 148:844-852.
  • Schneider LS, Small CW, Hamilton SH. (1997). Estrogen replacement and response to fluoxetine in a multi-center geriatric depression trial. Am J Geriatr Psychiatry, 5:97-106.
  • Schwartz LM, Fisher ES, Tosteson NA, et al.. (1997). Treatment and health outcomes of women and men in a cohort with coronary artery disease. Arch Intern Med, 157:1545-1551.
  • Shumaker SA, Legault C, Thal L, Wallace RB, Ockene JK, Hendrix SL, Jones BN 3rd, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J, WHIMS Investigators. (2003). Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA, 289(20):2651-2662.
  • Shapira B, Eppenheim G, Zohar J, et al.. (1985). Lack of efficacy of estrogen supplementation to imipramine in resistant female depressives. Biol Psychiatry, 20:576-579.
  • Sherwin, BB. (1991). The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. J Clin Endocrinol Metab 1991, 72:336-343.
  • Sherwin, BB and Suranyi-Cadotte, BE. (1990). Up-regulatory effect of estrogen on platelet 3H-imipramine binding sites in surgically menopausal women. Biol Psychiatry, 28:339-348.
  • Simkin-Silverman LR, Wing RR, Boraz MA, Kuller LH.(2003). Lifestyle intervention can prevent weight gain during menopause: results from a 5-year randomized clinical trial. Ann Behav Med. Dec;26(3):212-20.
  • Smuraskawa LT, Alexandrov AV, Bladin CF, Norris JW. (1994). Costs of acute stroke care in Toronto, Canada. Stroke, 25:1628-1631.
  • Soares CN, Almeida OP, Joffe H, Cohen LS. (2001). Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry, 58:529-534.
  • Society of Obstetricians and Gynaecologists of Canada. (2002). Press Release: SOGC cautions women not to overreact to US study. SOGC Press Release.
  • Stahl, SM. (1996). Essential psychopharmacology: neuroscientific basis and practical applications. Cambridge UK: Cambridge University Press.
  • Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R, Lawrence W, Hanfelt JJ, Hayes DF. (2000). A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. ANN ONCOL, 11:17-22.
  • Stearns V, Beebe KL, Iyengar M, Dube E. (2003). Paroxetine controlled release in the treatment of menopausal hot flashes. JAMA, 289:2827-2834.
  • Steingart RM, Packer M, Hamm P, et al.. (1991) Sex differences in the management of coronary artery disease. N Engl J Med, 325:226-230.
  • Stewart, DE and Boydell, K. (1993). Psychologic distress during menopause: associations across the reproductive life cycle. Int J Psychiatry Med, 23:57-62.
  • Sturgeon SR, Schairer C, Brinton LA, Pearson T, Hoover RN. (1995). Evidence of a healthy estrogen user survivor effect. Epidemiology, 6:227-231.
  • Subbiah, MT. (1998). Mechanisms of cardioprotection by estrogens. Proc Soc Exp Biol Med, 217:23-29.
  • Sullivan JM. Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM (1990). Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med, 150:2557-2562.
  • Suri R, Burt VK, Altshuler LL, Zuckerbrow-miller J, Fairbanks L. (2001). Fluvoxamine for postpartum depression. Am J Psychiatry, 158:1739-1740.
  • Taylor, M. (2001). Botanicals: medicines and menopause. Clin Obstet Gynecol, 44(4):853-863.
  • Tenenhouse A, Joseph L, Kreiger N, et al.(2000). Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int, 11:897-904.
  • Tremblay A, Sheeran L, Aranda SK. (2007).Psychoeducational interventions to alleviate hot flashes: a systematic review. Menopause. Jun 21
  • U.S. Preventive Services Task Force. (2002). Postmenopausal hormone replacement therapy for the primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med, 137(10):834-839.
  • Vaccarino V, Chen YT, Wang Y, Radford MJ, Krumholz HM. (1999). Sex differences in the clinical care and outcomes of congestive heart failure in the elderly. Am Heart J, 138:835-842.
  • van Baal WM, Smolders RG, van der Mooren MJ, Teerlink T, Kenemans P. (1999). Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol, 94:485-491.
  • van Baal MW, Emeis JJ, van der Mooren MJ, Kessel H, Kenemans P, Stehouwer CDA. (2000). Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomized, placebocontrolled 12-week study. Thromb Haemost, 83:29-34.
  • Wakatsuki A, Ikenoue N, Sagara Y. (1998). Effects of estrogen on susceptibility to oxidation of low-density and high-density lipoprotein in postmenopausal women. Maturitas, 28:229-234.
  • Ware, MR. (1997). Fluvoxamine: A review of the controlled trial in depression. J Clin Psychiatry, 58(Suppl 5):15-23.
  • Wathen CN, Feig DS, Feightner JW, Abramson B, Ch. (2004). Hormone replacement therapy for the primary prevention of chronic disease: recommendation statement by the Canadian Task Force on Preventive Health Care. CMAJ Canadian Medical Association Journal. May 11, 2004
  • Weitzner MA, Moncello J, MSN , ARNP , Jacobsen PB, Minton S. (2002). A pilot trial of Paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. J Pain Symptom Manag, 23:337-345.
  • Weintraub M, Grosskopf I, Charach G, Eckstein N, Rububstein A. (1999). Hormone replacement therapy enhances postprandial lipid metabolism in postmenopausal women. Metabolism, 48:1193-1196.
  • Welty FK, Lee KS, Lew NS, Nasca M, Zhou JR.(2007). The association between soy nut consumption and decreased menopausal symptoms. J Womens Health (Larchmt). Apr;16(3):361-9.
  • WHO Scientific Group on Research on the Menopause in the 1990s. (1996). WHO Technical Report Series. Geneva, Switzerland: WHO.
  • Wijma K, Melin A, Nedstrand E, Hammar M. (1997). Treatment of menopausal symptoms with applied relaxation: a pilot study. J Behav Ther Exp Psychiatry, 28:251-261.
  • Winkler UH, Aitkemper R, Kwee B, Helmond FA, Coelingh Bennink HJT. (2000). Effects of tibolone and continuous combined hormone replacement therapy on parameters of the clotting cascade: multicenter, double-blind, randomized study. Fertil Steril, 74: 10-19.
  • Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. (1991). Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol, 164:489-494.
  • Woods NF, Mitchell ES. (1996). Patterns of depressed mood in midlife women: observations from the Seattle Midlife Women's Health Study. Res Nurs Health, 19:111-123.
  • World Health Organization. (1998). Guidelines for preclinical evaluation and clinical trials in osteoporosis. Geneva: WHO 59.
  • Writing Group for the PEPI Trial. (1995). Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions Trial. JAMA, 273:199-208.
  • Writing Group for the Women's Health Initiative Investigators. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288:321-333.
  • Wuerst JH Jr, Dry TJ, Edwards JE. (1953). The degree of coronary atherosclerosis in bilaterally oophorectomized women. Circulation, 7:801-809.
  • Ziaei S, Kazemnejad A, Zareai M.(2007). The Effect of Vitamin E on Hot Flashes in Menopausal Women. Gynecol Obstet Invest. Jul 30;64(4):204-207
  • Zucker DR, Griffith JL, Beshansky JR, Selker HP. (1997). Presentations of acute myocardial infarction in men and women. J Gen Intern Med, 12:79-87.
  • Zung, WWK. (1965). A self-rating depression scale. Arch Gen Psychiatry, 12:63-70.
  • Zweifel, JE and O'Brien, WH. (1997). A meta-analysis of the effect of hormone replacement therapy upon depressed mood. Psychoneuroendocrinology, 22:189-212.

Top of Page


Accommodations for Disabilities                   Clinical Updates Email Sign Up                  Refund & Course Exchange Policies



      Twitter Facebook LinkedIn YouTube

Online CE Courses
CE Board Approvals
58 Essential Clinical Forms
HIPAA Compliance Kit
Private Practice Handbook
Private Practice Resources
Free Online Resources
Organizational Discounts
Site Map

Issues Facing Teenagers
Boundaries & Dual Relationships
About Us
Info for the General Public
ADA Policy & Grievance
Privacy, Disclaimer, Terms of Use, DMCA

© 1995 - 2018 ZUR INSTITUTE, Inc.             Ofer Zur, Ph.D., Director             Contact Zur Institute, Inc.